title: Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs.
abstract: OBJECTIVE
  To determine the anesthetic-sparing effect of maropitant, a neurokinin 1 receptor antagonist, during noxious visceral stimulation of the ovary and ovarian ligament in dogs.
  
  
  METHODS
  Eight 1-year-old female dogs.
  
  
  METHODS
  Dogs were anesthetized with sevoflurane. Following instrumentation and stabilization, the right ovary and ovarian ligament were accessed by use of laparoscopy. The ovary was stimulated with a traction force of 6.61 N. The minimum alveolar concentration (MAC) was determined before and after 2 doses of maropitant.
  
  
  RESULTS
  The sevoflurane MAC value was 2.12 ± 0.4% during stimulation without treatment (control). Administration of maropitant (1 mg/kg, IV, followed by 30 μg/kg/h, IV) decreased the sevoflurane MAC to 1.61 ± 0.4% (24% decrease). A higher maropitant dose (5 mg/kg, IV, followed by 150 μg/kg/h, IV) decreased the MAC to 1.48 ± 0.4% (30% decrease).
  
  
  CONCLUSIONS
  Maropitant decreased the anesthetic requirements during visceral stimulation of the ovary and ovarian ligament in dogs. Results suggest the potential role for neurokinin 1 receptor antagonists to manage ovarian and visceral pain.
authors: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA. pboscan@colostate.edu
authors: Pedro
authors: P
authors: Boscan
authors: Eric
authors: E
authors: Monnet
authors: Khursheed
authors: K
authors: Mama
authors: David C
authors: DC
authors: Twedt
authors: Jonathan
authors: J
authors: Congdon
authors: Eugene P
authors: EP
authors: Steffey
mesh_terms: D000769:Anesthesia, Inhalation / Q000662:veterinary; D018685:Anesthetics, Inhalation / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004285:Dogs / Q000378:metabolism*; D005260:Female; D007262:Infusions, Intravenous / Q000662:veterinary; D010535:Laparoscopy / Q000662:veterinary; D008022:Ligaments / Q000503:physiopathology; D008738:Methyl Ethers / Q000008:administration & dosage* / Q000493:pharmacokinetics; D064729:Neurokinin-1 Receptor Antagonists; D010053:Ovary / Q000503:physiopathology; D011650:Pulmonary Alveoli / Q000378:metabolism; D011812:Quinuclidines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077149:Sevoflurane; D059265:Visceral Pain / Q000517:prevention & control / Q000662:veterinary*
chemical_list: D018685:Anesthetics, Inhalation; D000932:Antiemetics; D008738:Methyl Ethers; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; D000077149:Sevoflurane; C518176:maropitant